Tern secures £45,000 bridging loan ahead of open offer

Tern Plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that ahead of the expected receipt of funds from the Company’s underwritten open offer to raise approximately £642,486 (before expenses) announced on 14 July 2025, Tern has received a bridging loan, which has been provided by a vehicle controlled by Al Sisto, non-board CEO of Tern, for the amount of approximately £45,000.

The proceeds of the Bridging Loan will be utilised to fulfil a commitment to one of Tern’s investments, and in doing so will allow Tern to retain its rights in relation to this investment, and for general corporate purposes until the expected receipt of funds from the Underwritten Open Offer, which is expected to be on or around 31 July 2025. As at 30 June 2025, the Company’s unaudited cash balance was approximately £70,000.

The Bridging Loan is an unsecured loan that is repayable on 1 August 2025, which is following the expected receipt of funds from the Underwritten Open Offer. The effective annual interest rate on the Bridging Loan is approximately 12%, which equates to approximately £150 during the term of the loan.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern notes automotive momentum at Device Authority

Tern Plc notes that Device Authority, in which it holds a 25.3% stake, has announced further progress in the automotive sector, securing a new OEM customer and expanding an existing Tier 1 deployment.

Key management emerges as a delivery risk in automotive software

Key management is becoming a delivery-critical constraint in software-defined vehicles, influencing risk, compliance and programme scalability.

Pharma teams gain early insight into message effectiveness

Talking Medicines gives pharma teams early insight into which messages resonate with healthcare professionals.

Talking Medicines joins 2026 UK AI Index

Talking Medicines joins the UK AI Index 2026, confirming its growing role in data-driven healthcare strategy.

AI in Healthcare 2025

In 2025, AI began reshaping healthcare delivery and marketing with practical applications, signalling a maturing investment landscape.

Talking Medicines targets messaging risk in pharma brand strategy

Talking Medicines reduces messaging risk for pharma brands by measuring real-time HCP response.

Search

Search